Tislelizumab Bests Docetaxel in NSCLC Tislelizumab Bests Docetaxel in NSCLC

The new immunotherapy prolonged overall survival when compared with docetaxel in patients with locally advanced non-small cell lung cancer (NSCLC).Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news